Page 137 - 《中国药房》2021年8期

[49]
同病理类型腹泻的病理生理机制并不完全相同 。因 [12] SELIG D J，DELUCA J P，LI Q，et al. Saccharomyces
此，仅按年龄段来推荐用药剂量并不合理。今后有必要 boulardii CNCM I-745 probiotic does not alter the phar-
开展依据体质量及不同类型腹泻特点的相关用药研究， macokinetics of amoxicillin[J/OL]. Drug Metab Pers Ther，
以帮助临床制定更为合理的用药方案。此外，有关布拉 2020[2020-12-21]. http：//dx.doi.org/10.1515/dmpt-2019-
氏酵母菌的不良事件鲜有报道，但其在中心静脉置管患 0032. DOI：10.1515/dmpt-2019-0032.
[13] KOON H W，SU B，XU C，et al. Probiotic Saccharomyces
者中的不良反应仍然不应完全忽视。
boulardii CNCM I-745 prevents outbreak-associated
参考文献
Clostridium difficile-associated cecal inflammation in
[ 1 ] PLOTNIKOVA E Y，YU Z V. Place of probiotics in the
hamsters[J]. Am J Physiol Gastrointest Liver Physiol，
prevention and treatment of antibiotic-associated diar-
rhea[J]. Ter Arkh，2015，87（5）：127-131. 2016，311（4）：610-623.
[ 2 ] SILVERMAN M A，KONNIKOVA L，GERBER J S. Im- [14] TERCIOLO C，DAPOIGNY M，ANDRE F. Beneficial ef-
fects of Saccharomyces boulardii CNCM I-745 on clinical
pact of antibiotics on necrotizing enterocolitis and antibio-
tic-associated diarrhea[J]. Gastroenterol Clin North Am， disorders associated with intestinal barrier disruption[J/
2017，46（1）：61-76. OL]. Clin Exp Gastroenterol，2019[2020-12-21]. https：//
[ 3 ] MANTEGAZZA C，MOLINARI P，D’AURIA E，et al. pubmed. ncbi.nlm.nih.gov/30804678/. DOI：10.2147/CEG.
Probiotics and antibiotic-associated diarrhea in children：a S181590.
[15] HOSSAIN M N，AFRIN S，HUMAYUN S，et al. Identi-
review and new evidence on Lactobacillus rhamnosus
GG during and after antibiotic treatment[J]. Pharmacol fication and growth characterization of a novel strain of
Res，2018，128：63-72. Saccharomyces boulardiiisolated from soya paste[J/OL].
[ 4 ] CAI J，ZHAO C，DU Y，et al. Comparative efficacy and Front Nutr，2020[2020-12-21]. http：//dx.doi.org/10.3389/
tolerability of probiotics for antibiotic-associated diarrhea： fnut.2020.00027. DOI：10.3389/fnut.2020.00027.
systematic review with network meta-analysis[J]. United [16] FLOCH M H，WALKER W A，SANDERS M E，et al. Re-
commendations for probiotic use：2015 update：procee-
Eur Gastroenterol J，2018，6（2）：169-180.
dings and consensus opinion[J]. J Clin Gastroenterol，
[ 5 ] NASIRI M J，GOUDARZI M，HAJIKHANI B，et al. Clo-
stridioides（Clostridium）difficile infection in hospitalized 2015，49（Suppl 1）：S69-S73.
patients with antibiotic-associated diarrhea：a systematic [17] MCFARLAND L V. From yaks to yogurt：the history，de-
review and meta-analysis[J]. Anaerobe，2018，50（1）：32- velopment，and current use of probiotics[J]. Clin Infect
37. Dis，2015，60（Suppl 2）：S85-S90.
[ 6 ] GUO Q，GOLDENBERG J Z，HUMPHREY C，et al. Pro- [18] NEUT C，MAHIEUX S，DUBREUIL L J. Antibiotic sus-
biotics for the prevention of pediatric antibiotic-associated ceptibility of probiotic strains：is it reasonable to combine
diarrhea[J]. Cochrane Database Syst Rev，2019，4（4）： probiotics with antibiotics? [J]. Med Mal Infect，2017，47
CD004827. （7）：477-483.
[ 7 ] GOLDENBERG J Z，YAP C，LYTVYN L，et al. Probiot- [19] OFFEI B，VANDECRUYS P，DE GRAEVE S，et al.
ics for the prevention of Clostridium difficile-associated Unique genetic basis of the distinct antibiotic potency of
diarrhea in adults and children[J/OL]. Cochrane Database high acetic acid production in the probiotic yeast Saccha-
Syst Rev，2017[2020-12-21]. https：//doi.org/10.1002/1465- romyces cerevisiae var. boulardii[J]. Genome Res，2019，
1858.CD006095.pub3. DOI：10.1002/14651858.CD006095. 29（9）：1478-1494.
pub4. [20] MEIER-DÖRNBERG T，KORY OI，JACOB F，et al.
[ 8 ] CZERUCKA D，RAMPAL P. Diversity of Saccharomyces Saccharomyces cerevisiae variety diastaticus friend or
boulardii CNCM I-745 mechanisms of action against in- foe：spoilage potential and brewing ability of different Sac-
testinal infections[J]. World J Gastroenterol，2019，25 charomyces cerevisiae variety diastaticusyeastisolates by
（18）：2188-2203. genetic，phenotypic and physiological characterization[J/
[ 9 ] KABBANI T A，PALLAV K，DOWD S E，et al. Prospec- OL]. Fems Yeast Res，2018[2020-12-21]. http：//dx.doi.
tive randomized controlled study on the effects of Saccha- org/10.1093/femsyr/foy023. DOI：10.1093/femsyr/foy023.
romyces boulardii CNCM I-745 and amoxicillin-clavula- [21] EDWARDS I L，GITSHAM P，BURTON N，et al. Geno-
nate or the combination on the gut microbiota of healthy typic and physiological characterization of Saccharomy-
volunteers[J]. Gut Microbes，2017，8（1）：17-32. ces boulardii，the probiotic strain of Saccharomyces cere-
[10] STIER H，BISCHOFF S C. Saccharomyces boulardii visiae[J]. Appl Environ Microbiol，2007，73（8）：2458-
CNCM I-745 influences the gut-associated immune sys- 2467.
tem[J]. MMW Fortschr Med，2017，159（Suppl 5）：S1-S6. [22] PAIS P，ALMEIDA V，YILMAZ M，et al. Saccharomyces
[11] RUI X，MA S X. A retrospective study of probiotics for boulardii：what makes it tick as successful probiotic? [J]. J
the treatment of children with antibiotic-associated diar- Fungi（Basel），2020，6（2）：78.
rhea[J]. Medicine，2020，99（23）：e20631. [23] MCFARLAND L V. The microbiota in gastrointestinal

中国药房 2021年第32卷第8期 China Pharmacy 2021 Vol. 32 No. 8 ·1023 ·